Drugs / Dorzagliatin
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT06995651 | Oct 2025 → Jul 2027 expected | cystic fibrosis-related diabetes, exocrine pancreatic insufficiency | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1 | NCT04324424 | Apr → Sep 2019 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT03790787 | Apr 2019 → Mar 2020 | — | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT04426708 | Feb 2019 → Jul 2020 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT03790839 | Jan → Aug 2019 | — | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT04080609 | Mar → Apr 2018 | — | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT04080596 | Oct → Dec 2017 | — | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT03158506 | Mar → Apr 2017 | — | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT02597400 | Oct 2015 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT02386982 | Mar → May 2015 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT02077452 | Mar → Sep 2014 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 1 | NCT01952535 | Sep → Dec 2013 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04531631 | Sep 2020 → Feb 2022 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT02561338 | Sep 2015 → Sep 2016 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05098470 | Mar 2022 → Jul 2025 overdue | type 2 diabetes mellitus | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03141073 | Oct 2017 → Feb 2021 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 3 | NCT03173391 | Jul 2017 → Nov 2020 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06263348 | Jan 2024 → Dec 2025 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06671340 | Apr → Dec 2025 overdue | type 2 diabetes mellitus | Elaine Chow | Not yet recruiting | No outcome recorded |
| — | NCT06222476 | Feb 2024 → May 2025 | diabetic kidney disease | Yan Bi | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05468229 Comparator | Aug 2022 → Apr 2023 | glucose intolerance | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06976658 Comparator | Apr 2025 → Dec 2026 expected | monogenic diabetes | Chinese University of Hong Kong | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dorzagliatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04531631 ↗ |
| Known as | Dorzagliatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297508 ↗ |
| Known as | Dorzagliatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297508 ↗ |
| Known as | HMS5552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04426708 ↗ |
| Known as | RO-5305552 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297508 ↗ |
| Known as | Sinogliatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297508 ↗ |
| Action | Activate | “GK activator HMS5552” NCT02597400 ↗ |
| Modality | Small molecule | — CHEMBL4297508 ↗ |
| Route | Oral | “Each study subject will receive a single oral dose of HMS5552.” NCT01952535 ↗ |
| Target | GCK | “dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase” PMID 35551292 ↗ May 2022 |